Edgewise Therapeutics, Inc. (EWTX) News
Filter EWTX News Items
EWTX News Results
|Loading, please wait...|
EWTX News Highlights
- For EWTX, its 30 day story count is now at 3.
- Over the past 22 days, the trend for EWTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- RARE are the most mentioned tickers in articles about EWTX.
Latest EWTX News From Around the Web
Below are the latest news stories about Edgewise Therapeutics Inc that investors may wish to consider to help them evaluate EWTX as an investment opportunity.
BOULDER, Colo., February 24, 2022--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today reported financial results for the fourth quarter and full year of 2021 and recent business highlights.
In this article, we discuss the top 10 stock picks of Samuel Isaly’s OrbiMed Advisors. If you want to skip our detailed analysis of Isaly’s history, investment philosophy, and hedge fund performance, go directly to Top 5 Stock Picks of Samuel Isaly’s OrbiMed Advisors. Samuel Isaly graduated from Princeton University with an A.B. in Economics […]
Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16
BOULDER, Colo., February 02, 2022--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in a fireside discussion and one-on-one investor meetings at the SVB Leerink Virtual 11th Annual Global Healthcare Conference, on February 16, 2022.
Edgewise Therapeutics (EWTX) presents Topline results from the Phase 1b study of EDG-5506 - Slideshow
No summary available.
Less than two weeks into the new year, the key question is coming clear: should we buy the dip? The markets are swooning a bit, so far in January. Both the S&P 500 and the NASDAQ are registering losses in 2022’s cumulative trading sessions – 2% on the S&P, and 4.5% on the NASDAQ. A combination of headwinds and tailwinds are pushing on equities. The former include the Omicron wave of COVID-19, as well as ongoing disruptions in the supply chains and labor markets. On the positive side, Omicron is
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) yesterday. The company's shares closed last Wednesday at $18.97. According to TipRanks.com, Schwartz is a 4-star analyst with an average return of 4.5% and a 44.6% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edgewise Therapeutics with a $33.00 average price target, representing a 74.0% upside. In a report released today, J.P. Morgan also maintained a Buy rating on the stock with a $33.00 price target.
Intel, NexGen Energy, Wex, Stereotaxis and Edgewise Therapeutics are five top stock gainers for Wednesday
Edgewise Therapeutics Inc (NASDAQ: EWTX) posted positive topline results from Phase 1b trial of EDG-5506, designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dystrophy (DMD) and Becker Muscular Dystrophy (BMD) The seven adults with BMD enrolled in the Phase 1b clinical trial were administered 20 mg oral doses of EDG-5506 (n=5) or placebo (n=2). EDG-5506 was shown to be well-tolerated with no discontinuations or dose reductions. Relat
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
BOULDER, Colo., January 05, 2022--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive topline results from the BMD, or Phase 1b, portion of a first-in-human Phase 1 clinical trial assessing the safety, tolerability, PK and pharmacodynamics (PD) of EDG-5506, an orally administered small molecule myosin inhibitor designed to pr
Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today announced plans to report topline results from the Phase 1b clinical trial of EDG-5506 in individuals with BMD on January 5, 2022, at 9:00 am ET. The webcast event will feature a presentation of the results which support advancement of the program, and comment